Navigation Links
Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
Date:7/28/2011

KYOTO, Japan, July 28, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced data from its clinical development program for OBI-1, an intravenous (IV) recombinant porcine factor VIII product (rpFVIII), intended for the treatment of bleeding in people with hemophilia A with inhibitors and in people with acquired hemophilia.  The data were presented in a Scientific Session held in conjunction with the 23rd Congress of the International Society on Thrombosis and Haemostasis (ISTH), which was chaired by Amy Shapiro, M.D., Co-Medical Director at the Indiana Hemophilia and Thrombosis Center (IHTC).

During the Scientific Session, Anne Greist, M.D., Co-Medical Director at IHTC, presented interim results from the first registration study in the OBI-1 Accur8 clinical trial program.  A total of three patients with acquired hemophilia, who had experienced severe bleeds not controlled with by-passing agents, were treated with OBI-1; in all three patients, treatment with OBI-1 stopped the bleeding.  Further data on hemostatic efficacy and safety are being collected as part of the Accur8 clinical trial program, designed to study OBI-1 in acquired hemophilia.  A second study in individuals with congenital hemophilia A who have developed inhibitors against FVIII is set to commence later this year.

Additional reports from the Scientific Session confirmed findings from the Phase 2 study in congenital hemophilia A with inhibitors; that OBI-1 effectively resulted in hemostasis, and controlled all non-life/non-limb threatening bleeding episodes in individuals with congenital hemophilia A and inhibitors, even in the presence of high inhibitor levels. All 25 bleeds in the study were controlled, and twenty out of 25 bleeds (80%) were controlled with two infusions. In over 40 infusions administered, OBI-1 was well tolerated by all participants and no drug-related serious adverse events were observed.

Dr. Gre
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
2. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
3. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
4. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. National Expressions of Courage Art Contest Unveils Stories of Inspiration
7. Inspiration for My Sisters Keeper Speaks Out
8. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
9. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
10. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
11. Reportlinker Adds India Biopharmaceuticals Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... our Medicare resources and continue highlighting the success of the prescription drug benefit, commonly ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today ... 2015. Key results include: , Total revenues ... 2014 to $5,370 million, with 6 percent product ... (etanercept), Prolia ® (denosumab), Sensipar ® ... (denosumab). Unfavorable changes in foreign exchange rates ...
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... Inc. (NYSE: WPI ) today announced that ... with Endo Pharmaceuticals, Inc. on outstanding patent litigation related ... its lawsuit on March 4, 2010, following Watson,s filing ... U.S. Food and Drug Administration (FDA) for seeking approval ...
... Inc. (Nasdaq: AKRX ) will host a conference ... results followed by a Q&A session.  The company will release ... Akorn Third Quarter 2010 Conference CallDate/Time: , Tuesday, November ... (888) 215-6895International Callers: , (913) 312-0860Confirmation Code: , ...
Cached Medicine Technology:Watson Reaches Settlement with Endo Over Opana® ER 2
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, which ... Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the ... message including ones already sent. , While text messaging has more features than it ...
(Date:7/31/2015)... York, New York (PRWEB) , ... July 31, 2015 , ... ... to strut their stuff, Super-Sod debuted their new type of sod called Leisure ... registered trademark application in process. , To commemorate introduction of this new type of ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Precision Aesthetics is ... years. It was also the first provider of Exilis non-surgical fat reduction in ... after procedures it has attracted a large International clientele. Many patients travel to ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Sculpted ... , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in ... in January 2014 for treating the outer thighs. The original applicator required a ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Study Defining Mechanism,and Potential Treatment for Rett Syndrome, Leading ... trial to test molecule in humans is being planned ... to other forms of autism - , BOSTON ... research, clinical and family collaboration dedicated to radically accelerating ...
... 9 Immtech Pharmaceuticals, Inc. (NYSE Alternext: IMM) today ... 31, 2008.For the three months ended December 31, 2008, ... three months ended December 31, 2007. The decrease ... a research and testing agreement. Loss from operations ...
... The Emergency Nurses Association (ENA) today announced the corporate sponsors ... Nevada on March 4 - 8, 2009.This year,s sponsors are ... pleased that these two companies have chosen to support emergency ... ENA Leadership Conference," said William T. Briggs, RN, MSN, CEN, ...
... ANN ARBOR, Mich., Feb. 9 A research brief ... percent of children used,health services due to influenza-like illness ... than double the rate for adults. , ... children used healthcare,services for ILI than families without children ...
... of cardiovascular disease, cancer , , MONDAY, Feb. 9 (HealthDay ... supplement industry, researchers find no evidence that multivitamin use ... the top two killers of women, respectively. , "Women ... seem to do no harm, but they also seem ...
... & IVF Institute,s New SALUTE(TM) Program Honors Military FAIRFAX, Va., ... that it is offering special discounts on in vitro fertilization ... of the military who retired after at least twenty years ... a 25% per cycle discount on single cycles of in ...
Cached Medicine News:Health News:Autism Consortium members publish in PNAS: Mechanism, treatment for Rett syndrome -- top cause autism girls 2Health News:Autism Consortium members publish in PNAS: Mechanism, treatment for Rett syndrome -- top cause autism girls 3Health News:Immtech Reports Fiscal Third Quarter 2009 Results 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 3Health News:Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 2Health News:Kids and Their Families Are Hit Hardest During Flu Season, According to Thomson Reuters Study 2Health News:Vitamins Do Older Women Little Good 2Health News:Vitamins Do Older Women Little Good 3Health News:Special Discounts On Fertility Treatment For Active Duty and Retired Military 2
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish....
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees....
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish....
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: